Data are available from the Comité de Etica en Investigación and Comité de Investigación (contact by phone +525556280400 ext. 37015 or email: <comite.cientifico.incan@gmail.com>) for researchers who meet the criteria for access to confidential data. An anonymized data set are available within the paper and its Supporting Information files.

Introduction {#sec004}
============

*Acinetobacter baumannii* has become a major hospital pathogen, due to multidrug resistant (MDR) strains and it is now considered one of the six most important microorganisms that causes hospital-acquired infections worldwide, with attributable mortality ranging from 8% to 35% according to strain and type of infection as well as increase in hospital stays and health care expenditures \[[@pone.0234684.ref001],[@pone.0234684.ref002]\]. Bloodstream infection (BSI) and pneumonia, especially ventilator-associated pneumonia (VAP), are the most severe infections caused by this gram-negative bacterium \[[@pone.0234684.ref003],[@pone.0234684.ref004]\].

Carbapenems have been considered the drugs of choice to treat *A*. *baumannii* infections. These drugs are still the first-line agents for empirical therapy in areas with high rates of susceptibility \[[@pone.0234684.ref003]\]. However, the extensive use of carbapenems for the treatment of cephalosporin-resistant *Enterobacteriaceae* has been regarded as one of the main risk factors promoting the emergence and spread of multidrug-resistant (MDR) *A*. *baumannii* strains.

The role of the environmental contamination in the transmission of nosocomial infections in general and in *A*. *baumannii* infections in particular is well recognized \[[@pone.0234684.ref005]\]. This pathogen is able to grow at various temperatures and pH conditions, so it has the ability to persist in either moist or dry conditions in the hospital environment, thereby contributing to transmission \[[@pone.0234684.ref006], [@pone.0234684.ref007], [@pone.0234684.ref008]\]. We documented an outbreak of an MDR *A*. *baumannii* strain identified initially in 2011 in the intensive care unit (ICU) that lasted until 2015. The strain was introduced by an infected patient transferred from another hospital. This study aimed to identify the epidemiology of the outbreak and to describe the clinical evolution and risk factors for adverse outcomes of patients during the outbreak of MDR *A*. *baumannii*.

Methods {#sec005}
=======

We conducted a retrospective study at Instituto Nacional de Cancerología (INCan), a 135-bed tertiary care oncology hospital located in Mexico City, with an average of 170,000 medical visits and 7,500 hospital discharges per year, taking care mainly of uninsured patients, and patients covered by the \"popular insurance\" design to offer a basic package of services for certain malignancies. The ICU has six beds, with a mean of 230 hospitalizations per year; 58% of them are surgical patients with solid tumors, 25% have hematologic malignancies, and 17% are patients with solid tumors on chemotherapy.

In March 2011, we isolated the first strain of MDR *A*. *baumannii*; since then, multiple isolates from different sources of hospitalized patients at the ICU were recovered. No MDR *A*. *baumanii* strains had been isolated previously in the hospital. During 2011 to 2012, 78 isolates were identified (73.6%), decreasing the number of isolates recovered in the coming three years, until 2015. From January 2011 to December 2015, 106 patients with MDR *A*. *baumannii* isolates were identified, all were included in the study. Each isolate was classified as infected or colonized according to the criteria of two independent infectious diseases (ID) clinicians. A case was defined when the patient exhibited signs and symptoms of infection with or without a systemic inflammatory response. Bloodstream infection (BSI) was defined as laboratory-confirmed isolation of *A*. *baumannii* from blood cultures. Pneumonia was considered when new or progressive infiltrates on x-ray appeared with at least two of the following parameters: fever (\>38°C) or hypothermia (\<35.5°C), leukocytosis (\>12,000 cells/ml) or leukopenia (\<4000 cells/ml), and positive bronchial aspirate culture \[[@pone.0234684.ref009]\]. Urinary tract infection was considered in those patients who present dysuria or hematuria and frequency or urgency, and urinalysis with pyuria and bacteriuria or positive nitrites. Surgical site infection defined as the infection in the part of the body where the surgery took place and occurring within 30 days after the operation. Airway colonization was defined if *A*. *baumannii* was isolated without symptoms of infection, and did not receive specific antimicrobial therapy. If there was a disagreement between the two physicians, a third ID physician analyzed the case, and a consensus was reached.

Clinical information was collected from the medical charts, including type of oncological disease, clinical stage (recent diagnosis, progression, relapse, partial or complete remission), recent chemotherapy or surgery (less than one month), recent hospitalization or antimicrobial use (previous 3 months), length of hospital stay, ICU admission and length of ICU stay, SOFA (Sequential Organ Failure Assessment) at ICU admission and at the date from *A*. *baumannii* culture was taken, days on mechanical ventilation, antimicrobial regimen, and outcome at 72 hours and at 30 days (alive, death attributable to infection, death related to neoplasm, or death due to other cause). Appropriate antimicrobial regimen was considered if it included colistin or tigecycline for ≥48 hours within the first 24 hours from isolation.

*A*.*baumannii* was isolated from clinical specimens submitted to the microbiology laboratory; identification and antimicrobial susceptibility were determined using the Gram-Negative Identification Panel (BDPhoenix^TM^ automated system, New Jersey, USA). Identification of genotypic strains was confirmed by matrix-assisted laser desorption and ionization-time of flight mass spectrometry (MALDI-TOF-MS; Microflex, USA). MDR strains were tested for antibiotic disks on Mueller-Hinton agar containing colony suspension of *A*. *baumannii* equivalent to a 0.5 McFarland, Clinical and Laboratory Standards Institute (CLSI) recommendations for susceptibility \[[@pone.0234684.ref010]\]. Antibiotic disks included ceftriaxone (30 μg), ceftazidime (30 μg), ciprofloxacin (5 μg), imipenem (10 μg), meropenem (10 μg), gentamicin (10 μg), and sulfamethoxazole/trimethoprim (SXT-1.25/23.75 μg) (CLSI). Colistin (10 μg) disks were tested although no parameters had been determined by CLSI. All isolates had an inhibition zone diameter ≥21 mm. \[[@pone.0234684.ref010]\]. Strains are considered MDR if they showed resistance to more than one agent in ≥3 antimicrobial categories such as aminoglycosides, antipseudomonal carbapenems and/or cephalosporins, fluoroquinolones, beta-lactam-beta-lactamase inhibitors, folate pathway inhibitors, and tetracyclines (Magiorakos criteria) \[[@pone.0234684.ref011]\]. All the strains included in this study, were resistant to all previous antibiotics families except tetracyclines and colistin. MICs reported were: ceftriaxone \>32, ceftazidime \>2, ciprofloxacin \>2, imipenem \>8, meropenem \>8, gentamicin \>8, and SXT \>2/38. Strains were preserved and stored in glycerol at -70°C for further analysis.

DNA was extracted from a representative strain of each pattern (Genomic DNA Purification Kit, Thermo Scientific) for subsequent PCRs. First, rpoB's Zone-1 \[[@pone.0234684.ref012]\] was amplified and sequenced to confirm taxonomic status. Plasmid profiles of each isolate were obtained during the study period with the modified Eckhardt protocol ([S1 File](#pone.0234684.s001){ref-type="supplementary-material"}) \[[@pone.0234684.ref013],[@pone.0234684.ref014]\]. Each plasmid pattern was given an arbitrary roman numeral and used to group the strains. Strains confirmed as *A*. *baumannii* by their best hit against the NCBI database (at least 99% identity) were subject to MultiLocus Sequence Typing (MLST) scheme (Bartual) \[[@pone.0234684.ref015]\]. All PCR fragments were cloned in pJET1.2 (Thermo Scientific) and subject to Sanger sequencing with pJET universal oligonucleotides. *A*. *baumannii* MLST sequences were queried against the pubMLST database (<http://pubmlst.org>) to get their sequence type (ST). An ST number was requested to pubMLST for each one of the isolates with a new MLST profile.

Statistical analysis {#sec006}
--------------------

Categorical variables were described by frequencies and percentages. Quantitative variables were described by means, standard deviation, medians, and quartiles according to distribution. Univariate analysis was performed using Student's *t*-test or Mann-Whitney U test for continuous variables, and Chi-square or Fisher's exact test was used to compare categorical variables. Variables with P values ≤0.5 in the univariate analysis were included in the multivariate analysis. Rates of overall survival were estimated using the Kaplan Meier method and log rank test. P values \<0.05 were considered statistically significant. Data were analyzed using STATA (ver. 14) software.

Ethics {#sec007}
------

The study was approved by the INCan Ethics Review Board (Rev/0009/19). No consent form was required; patient´s information was anonymous and de-identified prior to analysis.

Results {#sec008}
=======

During the study period, 108 patients with MDR *A*. *baumannii* isolates were identified: two were excluded because *rpoB* sequencing one was identified as *A*. *haemolyticus* and one as *Acinetobacter spp*. There were included 106 patients with isolates from the following sources: blood (n = 18), bronchial aspirates (n = 49), surgical site infection (n = 20), urine (n = 12), pleural fluid (n = 4), biopsies (n = 2) and catheter tip (n = 1). Fourteen patients had MDR-*A*. *baumannii* isolated from two different clinical sites and three patients had the isolation from three different sites. Forty-one strains were isolated in 2011 (37.7%), 37 in 2012 (34.9%), 12 in 2013 (11.3%), 13 in 2014 (12.2%), and 3 in 2015 (2.83%). Sixty-six (62.3%) isolates were considered as infection and 40 (37.7%) were classified as colonization ([Fig 1](#pone.0234684.g001){ref-type="fig"}).

![Number of infected (1a) and colonized (1b) patients during the study period (2011--2015) divided into alive or dead, including the plasmid profile.](pone.0234684.g001){#pone.0234684.g001}

The index case was identified by molecular epidemiological analysis; was an infected hemato-oncological patient with a pleural drainage, who was transferred from another hospital outside Mexico City.

Of all the isolates obtained during the outbreak, 99 had the same sequence type MLST 758; 94 had the same plasmid profile as the one recovered from the index case, two had the same plasmid an extra plasmid, and two others were also MLST 758 but had different plasmid profiles. Seven had different MLST (four of them proceeded from infected patients and had been hospitalized in another hospital within the previous 60 days).

Representative plasma profiles of selected *Acinetobacter* strains are shown in [Fig 2](#pone.0234684.g002){ref-type="fig"}.

![Plasmid profiles of *Acinetobacter* strains.\
Lanes marked with roman numerals are plasmid profiles isolated from *Acinetobacter baumannii*. Unmarked lanes are plasmid profiles of other *Acinetobacter* species isolated during this study period. Plasmid profile (strain number): V (2161), VIII (2339), X (3108), XII (3496), XIII (5189), XVI (4197), XVII (6793), XVIII (2275), XIX (2663), XXI (3275).](pone.0234684.g002){#pone.0234684.g002}

From the whole group, there were 59 men (55.6%); the mean age was 48.3 ± 16 years. Half of patients had a hematologic malignancy (*n* = 52, 49.1%), 66 (62.3%) had recent cancer diagnosis, 44 (41.5%) were receiving chemotherapy, and 28 (26.4%) had major surgery. Hematologic malignancies were more common in the infected group (76.9%) than in the colonization group (30%, *p* = 0.002). Also, there were more patients with hematologic malignancies classified as infected (60.6%) compared with patients with solid tumors (39.4%, *p* = 0.002). In the infected group, there were more patients (28.8%) who had received broad-spectrum antimicrobials during the previous three months vs. the colonization group (17.5%, *p* = 0.048). Other clinical and demographic characteristics are shown in [Table 1](#pone.0234684.t001){ref-type="table"}.

10.1371/journal.pone.0234684.t001

###### Demographic and general characteristics of 106 patients with MDR- *A*. *baumannii*, classified as colonized or infected.

![](pone.0234684.t001){#pone.0234684.t001g}

  Characteristics N (%)                                                                    Total--N = 106   Colonization--n = 40 (37.7)   Infection--n = 66 (62.3)   *P*
  ---------------------------------------------------------------------------------------- ---------------- ----------------------------- -------------------------- -------
  Age (years)[^a^](#t001fn001){ref-type="table-fn"}                                        48.3 ± 16        51.1 ± 16                     46.5 ± 15.9                0.156
  Male gender                                                                              59 (55.7)        21 (52.5)                     38 (57.6)                  0.610
  Solid tumor                                                                              54 (50.9)        28 (70)                       26 (39.4)                  0.002
  Hematologic malignancy                                                                   52 (49.1)        12 (30)                       40 (60.6)                  
  Oncologic status                                                                                                                                                   0.393
  Recent diagnosis                                                                         66 (62.3)        23 (57.5)                     43 (65.2)                  
  Progression                                                                              13 (12.2)        5 (12.5)                      8 (12.1)                   
  Relapse                                                                                  12 (11.3)        4 (10)                        8 (12.1)                   
  Complete remission                                                                       9 (8.5)          6 (15)                        3 (4.5)                    
  Partial remission                                                                        6 (5.7)          2 (5)                         4 (6.1)                    
  Recent chemotherapy[^b^](#t001fn002){ref-type="table-fn"}                                44 (41.6)        14 (35)                       30 (45.5)                  0.289
  Recent radiotherapy[^c^](#t001fn003){ref-type="table-fn"}                                10 (9.4)         2 (5)                         8 (12.1)                   0.311
  Previous hospitalization[^b^](#t001fn002){ref-type="table-fn"}                           55 (51.9)        20 (50)                       35 (53)                    0.762
  Median length of previous hospitalization[^d^](#t001fn004){ref-type="table-fn"} (days)   10 (5,17)        9 (4, 218)                    10 (5,15)                  0.881
  Recent use of antimicrobials[^b^](#t001fn002){ref-type="table-fn"}                       26 (24.5)        7 (17.5)                      19 (28.8)                  0.048
  Severe neutropenia                                                                       16 (15.1)        5 (12.5)                      11 (16.7)                  0.780
  Major surgery                                                                            28 (26.4)        16 (40)                       12 (18.2)                  0.013

^a^Mean ± standard deviation.

^b^During the previous three months.

^c^During the previous 6 months.

^d^Median (IQR).

Sixty-six patients (62.2%) were hospitalized in the ICU; the most common causes of ICU admission were: septic shock in 25 patients (37.9%) (eight related to *A*. *baumannii* infection, median of 12 days of hospitalization), and respiratory failure in 20 patients (30.3%). SOFA score at admission was not different between infected vs. colonized patients (*p* = 0.344); however, it was significantly higher in infected vs. colonized patients at the day in which the sample with *A*. *baumannii* isolation was taken (median 7 vs. 0, p \< 0.001). Sixty-six patients (62.3%) were on mechanical ventilation, 37 (56.1%) developed VAP, with a median of 8 days (IQR 3, 20 days) from intubation until *A*. *baumannii* isolation. [Table 2](#pone.0234684.t002){ref-type="table"}.

10.1371/journal.pone.0234684.t002

###### Clinical characteristics related to *A*. *baumannii* isolation in 106 patients, classified as colonized or infected.

![](pone.0234684.t002){#pone.0234684.t002g}

  Characteristics                                                                                                                           Total         Colonization   Infection      P
  ----------------------------------------------------------------------------------------------------------------------------------------- ------------- -------------- -------------- ---------
  Site of *Acinetobacter* isolation                                                                                                                                                     \<0.001
  Blood cultures                                                                                                                            18 (17)       0              18 (27.3)      
  Bronchial aspirate                                                                                                                        49 (46.2)     19 (47.5)      30 (45.4)      
  Surgical site infection                                                                                                                   20 (18.9)     15 (37.5)      5 (7.6)        
  Urine                                                                                                                                     12 (11.3)     3 (7.5)        9 (13.6)       
  Other                                                                                                                                     7 (6.6)       3 (7.5)        4 (6.1)        
  Hospital length before *A*. *baumannii* isolation (days)[^a^](#t002fn001){ref-type="table-fn"}                                            17.6 ± 13.6   21.6 ± 17.1    16.3 ± 12.51   0.136
  ICU hospitalization[^b^](#t002fn002){ref-type="table-fn"}                                                                                 66 (62.3)     20 (50)        46 (69.7)      0.046
  ICU stay before *A*. *baumannii* isolation (days)[^a^](#t002fn001){ref-type="table-fn"}                                                   10.1 ± 8.9    12 ± 11.4      9.3 ± 7.7      0.297
  ICU whole length stay (days)[^a^](#t002fn001){ref-type="table-fn"}                                                                        15.9 ± 12.6   15.8 ± 12.5    16 ± 12.8      0.931
  SOFA at ICU admission[^a^](#t002fn001){ref-type="table-fn"}[^c^](#t002fn003){ref-type="table-fn"}[^d^](#t002fn004){ref-type="table-fn"}   8 (5, 11)     7 (5, 10)      8 (6, 11)      0.344
  SOFA at *A*. *baumannii* isolation                                                                                                        3 (0, 9)      0 (0, 2)       7 (3,11)       \<0.001
  Mechanical ventilation (MV)                                                                                                               66 (62.3)     19 (47.5)      47 (71.2)      0.01
  Mean length of MV (days)[^a^](#t002fn001){ref-type="table-fn"}                                                                            15.2 ± 12.5   15.8 ± 12.4    15 ± 12.7      0.828
  *A*. *baumannii* isolated from bronchial aspirate after 48 h of MV[^e^](#t002fn005){ref-type="table-fn"}                                  37 (56.1)     14 (73.7)      23 (48.9)      0.100
  Days of MV until isolation[^a^](#t002fn001){ref-type="table-fn"}                                                                          12.6 ± 9.2    15.6 ± 12      10.8 ± 6.7     0.128
  Days from *A*. *baumannii* isolation until discharge[^d^](#t002fn004){ref-type="table-fn"}                                                8 (3, 20)     7 (4, 14)      9 (3, 22)      0.154
  Mortality at 72-hours                                                                                                                     21 (19.8)     1 (2.5)        20 (30.3)      \<0.001
  Mortality at 30-day                                                                                                                       53 (50)       8 (20)         45 (68.2)      \<0.001

^a^Mean ± standard deviation.

^b^ICU: Intensive Care Unit.

^c^SOFA (Sequential Organ Failure Assessment) at ICU admission were calculated in 66 patients: 20 colonized and 46 infected.

^d^Median (interquartile range).

^e^Percentage was obtained from the total of patients with mechanical ventilation.

Twenty-one patients (19.8%) died within 72 hours after *A*. *baumannii* isolation; 20 (95.2%) were classified as infected. During the first month, 53 patients (50%) died: 8 (20%) in the colonized group and 45 (68.2%) in the infected group (*p* \<0.001). ([Fig 3](#pone.0234684.g003){ref-type="fig"}). From the infected patients who died, 16/18 (88.9%) had BSI, 22/30 (73.3%) had pneumonia, and 7/18 (38.9%) had *A*. *baumannii* isolated from another site (*p* = 0.003). The time between *A*. *baumannii* isolation and death was shorter among patients whose strain was isolated from blood (median 3 days; IQR 2,5), compared with patients whose strain was isolated only from bronchial aspirates (median 8 days; IQR 3, 22), (*p* = 0.03).

![Kaplan Meier survival in 106 patients with *A*. *baumannii* divided by colonized (n = 40) or infected (n = 66).](pone.0234684.g003){#pone.0234684.g003}

Considering only the infected patients, 32 (48.5%) received an appropriate antibiotic against *A*. *baumannii*, of which 29 received colistin (four as monotherapy, fifteen combined with rifampicin, two with meropenem, eight with meropenem and rifampicin), the mean days of colistin were 12 ± 6 days (no differences between patients with BSI, with VAP or with other infection). Two patients received tigecycline (one as monotherapy and one combined with meropenem), for 7 and 14 days each one. Eighteen from 32 patients who received appropriate treatment died in the first 30 days (56.2%), compared with 27 from 34 patients (79.4%) who did not receive an appropriate treatment (*p* = 0.06).

In univariate analysis, infection vs. colonization, hematologic malignancies and inappropriate antimicrobial treatment were the risk factors significantly associated with 30-day mortality. In the multivariate regression analysis, infected patients and inappropriate antimicrobial treatment were the risks factors associated with death. [Table 3](#pone.0234684.t003){ref-type="table"}.

10.1371/journal.pone.0234684.t003

###### Uni- and multivariate analysis for 30-day mortality in patients MDR- *A*. *baumannii*.

![](pone.0234684.t003){#pone.0234684.t003g}

  Characteristics---*N* (%)                                     Alive (*n* = 53, 50%)   Death (*n* = 53, 50)   Univariate           Multivariate                       
  ------------------------------------------------------------- ----------------------- ---------------------- -------------------- -------------- ------------------- ---------
  Age ≤60 (years)                                               44 (83)                 40 (75.5)              1.6 (0.55--4.68)     0.473          \-                  
  Age ≥60                                                       9 (17)                  13 (24.5)                                                                      
  Colonized                                                     32 (60.4)               8 (15.1)               8.6 (3.12--24.86)    \<0.001        1                   \<0.001
  Infected                                                      21 (39.6)               45 (84.9)                                                  6.58 (2.34--18.5)   
  Solid tumor                                                   36 (67.9)               18 (33.9)              4.1 (1.7--10.1)      \<0.001        1                   0.03
  Hematologic malignancy                                        17 (32.1)               35 (66.1)                                                  2.12 (1.09--9.35)   
  Recent diagnosis/CR[^a^](#t003fn001){ref-type="table-fn"}     40 (75.5)               36 (67.9)              1.45 (0.57--3.73)    0.388          \-                  
  Progression/relapse                                           13 (24.5)               17 (32.1)                                                                      
  No recent chemotherapy                                        33 (62.3)               29 (54.7)              1.36 (0.58--3.19)    0.43           \-                  
  Recent chemotherapy[^b^](#t003fn002){ref-type="table-fn"}     20 (37.7)               24 (45.3)                                                                      
  Appropriate treatment[^c^](#t003fn003){ref-type="table-fn"}   8 (15.1)                29 (54.7)              2.9 (0.89--96)       0.06           1                   0.134
  Non-appropriate treatment                                     13 (24.5)               16 (30.2)                                                  2.03 (0.8--5.15)    
  SOFA score \<10[^d^](#t003fn004){ref-type="table-fn"}         48 (90.6)               37 (69.8)              3.78 (1.16--14.37)   0.02           1                   0.525
  SOFA score \>10                                               5 (9.4)                 16 (30.2)                                                  1.51 (0.42--5.41)   

^a^Recent oncology diagnosis or complete remission.

^b^Chemotherapy in the previous month.

^c^Analysis was performed only in those patients considered as infected.

^d^SOFA score. Sequential Organ Failure Assessment calculated when MDR-*A*. *baumannii* culture was taken.

Discussion {#sec009}
==========

We describe an outbreak that occurred from 2011 to 2015 (92.4% of the strains with MLST 758), peaking during 2011 and 2012 in the ICU, but persisting during the following years (2013 to 2015), including strains from patients hospitalized in wards outside the ICU. The strain was introduced into the institution by a patient (index case) with non-Hodgkin lymphoma transferred from another clinic outside Mexico City. MDR *A*. *baumannii* was isolated at arrival from the insertion site of a pleural tube. Initially, it was considered as a contaminant, and no treatment was prescribed. One week later, he developed respiratory failure, required mechanical ventilation, was admitted to the ICU and broad-spectrum antibiotics were administered. Three weeks after admission he received chemotherapy and seven days later he developed febrile neutropenia and MDR *A*. *baumannii* bacteremia was documented. He received colistin for 14 days and was transferred to another hospital still with clinical signs of serious infection. It has been demonstrated that *A*. *baumannii* is able to overcome specific and general host defense systems, and survive in contact with human host fluids and tissues \[[@pone.0234684.ref016]\].

In this series, we included 99 patients with an MLST 758 strain: 95 with the same plasmid profile (V), two with plasmid XVI- very similar to V, and two with another plasmid profile. The remaining seven isolates belonged to different MLSTs with different plasmids patterns; all of them have been hospitalized recently. They were probably colonized with the MDR strain when they arrived, and it became invasive during hospitalization due to therapeutic procedures.

This MLST has been identified previously in Mexican hospitals and in other countries of Latin America \[[@pone.0234684.ref017]--[@pone.0234684.ref019]\]. The MLST758 is an understudied lineage that does not belong to the international clones I and II; it has spread to Canada, Mexico, Honduras, and Colombia. This lineage represents a source of genetic diversity of MDR and XDR isolates that have not been studied \[[@pone.0234684.ref020], [@pone.0234684.ref021]\].

Currently, colistin seems to be the most reliably effective drug in vitro against MDR *A*. *baumannii* \[[@pone.0234684.ref001], [@pone.0234684.ref003]\]. The efficacy of this antibiotic in severe infections caused by *A*. *baumannii* has been demonstrated in several retrospective and prospective series including patients with serious infections such as pneumonia and bacteraemia \[[@pone.0234684.ref003]\].

In this study, 32 of the 66 patients classified as infected who received appropriate antimicrobial treatment had lower mortality (56.2%), than those who did not receive appropriate antimicrobial therapy (79.4%), although it was not statistically significant. There were two reasons why patients did not receive appropriate treatment:1) 21 patients died within 48 hours after culture was taken, and MDR *A*. *baumannii* had not been reported yet; 2) the other thirteen died because colistin was not regularly available in our hospital during 2011 and the first half of 2012. This high mortality in the first hours is related to extremely rapid clinical progression described in cases with *Acinetobacter* infection \[[@pone.0234684.ref022]\].

The last strain (isolated in 2015) was from a patient that already was infected when he arrived from another hospital from the west coast of Mexico. The plasmid profile was similar to the outbreak strain; we presume it was reintroduced to our hospital but did not spread further.

MDR *A*. *baumannii* isolation has increased during the last decades. In the 1970s, the majority of strains were sensitive to the commonly used antibiotics, but by 2007, up to 70% of isolates in certain settings were MDR, including some with resistance to carbapenems. Resistance is usually due to combined mechanisms, commonly including cell membrane impermeability, increased expression of efflux pumps, and production of beta-lactamases, commonly OXA type \[[@pone.0234684.ref023]\]. Exposure of *A*. *baumannii* to the selective pressure of potent antimicrobials has gradually led to a global prevalence of strains that are resistant to all beta-lactams, including carbapenems \[[@pone.0234684.ref023]\].

Recently, employing a population genomics approach, we described the emergence and dispersion of the lineage ST758, and also studied the antibiotic resistance mechanisms present in strains from this ST. This lineage emerged rather recently (about 22 years ago) and since then it has spread in many countries in Latin and North America; notably, strains from this lineage are not only carbapenem resistant but also multidrug resistant. In terms of acquired oxacillinases (OXAs), this lineage presents the worldwide-distributed OXA-23-like family but also the less disseminated OXA-40-like family \[[@pone.0234684.ref024]\].

Outbreaks caused by MDR *A*. *baumannii* have been identified in several ICUs worldwide, and the majority only susceptible to colistin \[[@pone.0234684.ref023]\]. Risk factors for MDR *A*. *baumannii* infections have been identified: previous hospitalization (the longer the stay, the higher the risk), use of invasive devices, surgical procedures, immunosuppression, admission to the ICU, mechanical ventilation, previous use of antibiotics, and colonization by this bacterium \[[@pone.0234684.ref003], [@pone.0234684.ref025]\]. In our series, 46% of patients had been hospitalized during the previous three months, 28% had used broad-spectrum antimicrobials, 83% had been admitted to the ICU, with a mean length of 16 days in the ICU and a mean length of 18 days in the hospital prior to *A*. *baumannii* isolation.

During the outbreak, prevention measures were implemented and others were reinforced; the measures included: a single nurse per patient, a single cleaning material quit per each room, exhaustive daily cleaning of all ventilation equipment, hand hygiene program reinforcement, strict contact isolation, chlorhexidine oral washing three times per day, and patient daily bathing with chlorhexidine. Antimicrobial control policies were implemented in year 2013. Also, for patients transferred from other hospital initial cultures from nares, axillary, perineal region and draining sites were taken. All the measures contributed to end the outbreak in year 2014. Environmental and tap water surveillance was also performed during the outbreak period (44 samples taken in 2011, and 111 in 2012). Only one tap water sample (isolated in Feb 2012) was positive for MDR *A*. *baumanniii* ST758 profile V at the hematopoietic stem cell transplant unit. No patient in this unit was diagnosed with MDR *A*. *baumanniii* infection.

Multiple studies have reported poor outcomes of MDR *A*. *baumannii* infection with high mortality rates and long hospital stays directly attributed to infection \[[@pone.0234684.ref026]\]. A study conducted in China found a crude and 30-day in-hospital mortality rate of MDR *A*. *baumannii* bacteremia of 21.2% and 12.7% respectively, lower than other reports in which high mortality rates ranged from 29% to 63.5%. This difference needs to be clarified as the severity of diseases and virulence factors are closely related to mortality \[[@pone.0234684.ref027]\]. A previous study carried out in Mexico reported 14.5% mortality \[[@pone.0234684.ref028]\]; this study included susceptible and resistant *A*. *baumannii* strains in a tertiary care teaching hospital; 22% of patients were not hospitalized in the ICU, which reflects less ill patients compared with this series. Mortality reported in this study was 20% in the first 72 hours, and 50% in the first month, in which patients with bacteremia had the highest mortality (89%). These results were similar to a retrospective cohort from Israel that reported increased mortality in patients with bacteremia and concomitant pneumonia \[[@pone.0234684.ref029]\]. As expected, the difference in mortality was significant when we compared colonized patients (20%) with infected patients (68.2%). Renal failure and SOFA score \>7 have been documented as independent risk factors for mortality in the ICU \[[@pone.0234684.ref027], [@pone.0234684.ref030]\]. We did not find differences in 30-day mortality when SOFA scores were analyzed at ICU admission, but we found differences when this score was calculated the day when culture was obtained (SOFA ≥10 was calculated in 30.2% of patients who died in the first month, compared with 9.4% who were alive in the same period of time, *p* = 0.02).

Although we did not estimate costs, it is very important to consider the increase in costs for the care of MDR organisms outbreaks. In France, the costs observed in a 17-week outbreak was close to 500,000 US dollars \[[@pone.0234684.ref004]\].

The study has some limitations: we included patients from a single tertiary-care referral cancer center, that does not allow to extrapolate the data to other scenarios. We also were not able to get information from resistance isolates of the hospital where the index patient was hospitalized previous to the transfer to our institution; we were able to establish through molecular epidemiology the original source of the strain.

However, the strengths are that it allows establishing some risk factors associated with infection and mortality from this pathogen, and we were able to demonstrate the clonal relation in most all the strains of this outbreak.

Conclusions {#sec010}
===========

The molecular epidemiology of this outbreak highlights the threat that represents the transfer of colonized patients with MDR strains from another institutions, and emphasizes the importance to adhere to strict preventive measures, particularly hand hygiene programs, and contact isolation in patients with MDR strains \[[@pone.0234684.ref030]\]. Although some of the strains collected had different plasmid patterns and did not belong to the main outbreak strain, they were obtained from patients that had been treated in other hospitals, which shows the constant menace of introducing MDR strains into a hospital.

Supporting information {#sec011}
======================

###### A method to obtain plasmid profiles from Acinetobacter.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript entitled "High mortality in an outbreak of multidrug resistant Acinetobacter baumannii introduced to an oncological hospital by a patient transferred from a general hospital." by Volkow-Fernández et al. reports an outbreak of multidrug resistant (MDR) A. baumannii

In my opinion the manuscript is of interest from an epidemiological and clinical point of view but the introduction, methods and discussion section are limited, I recommend presenting this manuscript in a better fashion. There are many errors in the document presented.

"We analyzed all MDR A. baumannii strains" How many?

"During the study period, 108 patients with MDR A. baumannii isolates were identified" 1 strain per patient?

"Fig 1a and 1b." No figures in the manuscript

"Of all the isolates obtained during the outbreak" How many?

The antibiotic resistance profile of the strains?

Did you know what kind of mechanism of resistance was behind the strains?

Please provide a comment in the discussion about detection of these strains in the micro lab and infection control.

What interventions were made in response to the outbreak

In colistin and Tigecycline treatment please include the dose and time according site of infection

Please include in the results and discussion the different ST found in the study

Please rewrite limitations of the study

Reviewer \#2: In this manuscript, the authors describe an outbreak of multidrug resistant Acinetobacter baumannii infection in a tertiary care cancer hospital in Mexico City. They describe the clinical features, outcomes, and molecular epidemiology of this outbreak.

Major comments

The clinical part of this work is complete. However, the absence of data concerning the antibiotic resistance profile for each strain is regrettable and must be shown since the antimicrobial susceptibility was determined, as described in the Methods part.

Furthermore, also regrettable, there is no figure with the experimental results of plasmid profile (agarose gels). It will be of interest to visualize these different profiles.

Specific comments

It is stated in the abstract that "we documented an outbreak of an MDR A. baumannii strain identified initially in 2011 \... " : Is there any clear evidence that all the strains isolated until 2015 are related to the index case ?

It could be of interest to show the relation between clinical data (localization, classification (infected or colonized), malignancies) and the sequence typing of the strain.

Why do the authors performed univariate and multivariate analysis ?

At the end of the Results part, it is stated that "98 had the same sequence type ST758". However, in the S1 table, it appears that 99 strains exhibit this ST. Could the authors clarify this point ?

The quality of the figures is poor. Furthermore, a detailed legend must be added for each figure.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Eduardo VIllacìs

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer 1. The manuscript entitled "High mortality in an outbreak of multidrug resistant Acinetobacter baumannii infection introduced to an oncological hospital by a patient transferred from a general hospital." By Volkow-Fernández et al. reports an outbreak of multidrug resistant (MDR A. baumannii).

In my opinion the manuscript is of interest from an epidemiological and clinical point of view but the introduction, methods and discussion section are limited, I recommend presenting this manuscript in a better fashion. There are many errors in the documented presented.

1\. "We analyzed all MDR A. baumannii strains". How many?

We included in methods the following (page 4, 2nd paragraph)

In March 2011, we isolated the first strain of MDR A. baumannii; since then, multiple isolates from different sources of hospitalized patients at the ICU were recovered. No MDR A. baumanii strains had been isolated previously in the hospital. During 2011 to 2012, 78 isolates were identified (73.6%), decreasing the number of isolates recovered in the coming three years, until 2015.

2\. During the study period, 108 patients with MDR A. baumannii isolates were identified 1 strain per patient?

We completed the phrase to make clear that was one strain per patient included (Page 4 line 11-12):

From January 2011 to December 2015, 106 patients with MDR A. baumannii isolates were identified, all were included in the study.

3\. Fig. 1a and 1b. No figures in the manuscript.

We checked and all figures were included in the built pdf form at submission.

4\. "Of all the isolates obtained during the outbreak" How many?

This information was incorporated in the methods section (page 4, line 11) also commented in in the answer of question 2

5\. The antibiotic resistance profile of the strains?

This information was incorporated in the text (Page 6, first paragraph).

All the strains included in this study, were resistant to all previous antibiotics families except tetracyclines and colistin.

6\. Did you know what kind of mechanism of resistance was behind the strains?

No, we have not investigated it.

7\. Please provide a comment in the discussion about detection of these strains in the micro lab and infection control. What interventions were made in response to the outbreak.

A comment was included about the detection in the microbiology laboratory and the measures taken to control the outbreak.

We incorporated in page 18, 2nd paragraph.:

During the outbreak, prevention measures were implemented and others were reinforced; the measures included: a single nurse per patient, a single cleaning material quit per each room, exhaustive daily cleaning of all ventilation equipment, hand hygiene program reinforcement, strict contact isolation, clorhexidine oral washing three times per day, and patient daily bathing with clorhexidine. Antimicrobial control policies were implemented in year 2013. Also, for patients transferred from other hospital initial cultures from nares, axillary, perineal region and draining sites were taken. All the measures contributed to end the outbreak in year 2014. Environmental and tap water surveillance was also performed during the outbreak period (44 samples taken in 2011, and 111 in 2012). Only one tap water sample (isolated in Feb 2012) was positive for MDR A. baumanniii ST758 profile V at the hematopoietic stem cell transplant unit. No patient in this unit was diagnosed with MDR A. baumanniii infection.

8\. In colistin and tigecycline treatment please include the dose and time according site of infection.

The information was included (Page 13, 2nd paragraph).

The mean days for colistin, the mean days were 12 ± 6 days (no differences between type of infection). Two patients received tigecycline (one as monotherapy and one combined with meropenem), for 7 and 14 days each one.

6\. Please include in the results and discussion the different MLST found in the study.

We have incorporated MLST findings in the results section (page 8, 2nd paragraph):

Of all the isolates obtained during the outbreak, 99 had the same sequence type MLST 758; 94 had the same plasmid profile as the one recovered from the index case, two had the same plasmid an extra plasmid, and two others were also MLST 758 but had different plasmid profiles. Seven had different MLST (four of them proceeded from infected patients and had been hospitalized in another hospital within the previous 60 days).

In the discussion section (Page 16, 2nd paragraph:

In this series, we included 99 patients with an MLST 758 strain: 95 with the same plasmid profile (V), two with plasmid XVI- very similar to V, and two with another plasmid profile. The remaining seven isolates belonged to different MLSTs with different plasmids patterns; all of them have been hospitalized recently. They were probably colonized with the MDR strain when they arrived, and it became invasive during hospitalization due to therapeutic procedures.

This MLST has been identified previously in Mexican hospitals and in other countries of Latin America. The MLST758 is an understudied lineage that does not belong to the international clones I and II; it has spread to Canada, Mexico, Honduras, and Colombia. This lineage represents a source of genetic diversity of MDR and XDR isolates that have not been studied \[12, 13\].

7\. Please rewrite limitations of the study

We incorporate a new version of the limitations of the study. (Page 19, last paragraph).

The study has some limitations: we included patients from a single tertiary-care referral cancer center, that does not allow to extrapolate the data to other scenarios. We also were not able to get information from resistance isolates of the hospital where the index patient was hospitalized previous to the transfer to our institution; we were able to establish through molecular epidemiology the original source of the strain.

However, the strengths are that it allows establishing some risk factors associated with infection and mortality from this pathogen, and we were able to demonstrate the clonal relation in most all the strains of this outbreak.

Reviewer \#2: In this manuscript, the authors describe an outbreak of multidrug resistant Acinetobacter baumannii infection in a tertiary care cancer hospital in Mexico City. They describe the clinical features, outcomes, and molecular epidemiology of this outbreak.

Major comments

The clinical part of this work is complete. However, the absence of data concerning the antibiotic resistance profile for each strain is regrettable and must be shown since the antimicrobial susceptibility was determined, as described in the Methods part.

1\. The information with the susceptibility was reviewed and some information was incorporated (Page 5, last paragraph).

Antibiotic disks included ceftriaxone (30 µg), ceftazidime (30 µg), ciprofloxacin (5 µg), imipenem (10 µg), meropenem (10 µg), gentamicin (10 µg), and sulfamethoxazole/trimethoprim (1.25/23.75 µg) (CLSI). Colistin (10 µg) disks were tested although no parameters had been determined by CLSI. All isolates had an inhibition zone diameter ≥21 mm. \[7\]. Strains are considered MDR if they showed resistance to more than one agent in ≥3 antimicrobial categories such as aminoglycosides, antipseudomonal carbapenems and/or cephalosporins, fluoroquinolones, beta-lactam-beta-lactamase inhibitors, folate pathway inhibitors, and tetracyclines (Magiorakos criteria) \[6\]. All the strains included in this study, were resistant to all previous antibiotics families except tetracyclines and colistin.

2\. Furthermore, also regrettable, there is no figure with the experimental results of plasmid profile (agarose gels). It will be of interest to visualize these different profiles.

The picture of an agarose gel showing the different profiles was included as figure 2.

Specific comments

3\. It is stated in the abstract that "we documented an outbreak of an MDR A. baumannii strain identified initially in 2011 \... " : Is there any clear evidence that all the strains isolated until 2015 are related to the index case ?

The same strain with the same plasmid profile isolated from the index case, that was a patients that had been transferred from a General Hospital to our Institution, was found in 100% of the isolates from the years 2011 to 2012, and in 93.4% from the whole strains.

4\. It could be of interest to show the relation between clinical data (localization, classification (infected or colonized), malignancies) and the sequence typing of the strain.

Ninety-nine of 106 strains had the same MLST, so only 7 patients had a different strain, we considered that the group is too small to do an analysis.

5\. Why do the authors performed univariate and multivariate analysis ?

The uni- and multivariate analyses were performed to assess clinical risk factors related to mortality and for colonization vs. infection.

6\. At the end of the Results part, it is stated that "98 had the same sequence type ST758". However, in the S1 table, it appears that 99 strains exhibit this ST. Could the authors clarify this point ?

There were 98 strains plus the index case, as the way it was written created confusion, we have modified the manuscript.

In the abstract section:

The index case, identified by molecular epidemiology, was a patient with a drain transferred from a hospital outside Mexico City. Ninety-eight additional cases had the same (MLST 758, of which 94 also had the same plasmid profile, two had an extra plasmid, and two had a different plasmid. The remaining seven isolates belonged to different MLSTs.

In the result section (Page 8, 2nd paragraph):

Of all the isolates obtained during the outbreak, 99 had the same sequence type MLST 758; 94 had the same plasmid profile as the one t recovered from the index case, two had the same plasmid an extra plasmid, and two others were also MLST 758 but had different plasmid profiles. Seven had different MLST (four of them proceeded from infected patients and had been hospitalized in another hospital within the previous 60 days).

7\. The quality of the figures is poor. Furthermore, a detailed legend must be added for each figure.

A new version of the figure much clearer with the corresponding figure legend (page 8, 3rd paragraph).

###### 

Submitted filename: Answer letter Reviewers Plow One March 2020.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234684.r003

Decision Letter 1

Cartelle Gestal

Monica

Academic Editor

© 2020 Monica Cartelle Gestal

2020

Monica Cartelle Gestal

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Apr 2020

PONE-D-19-33916R1

High mortality in an outbreak of multidrug resistant Acinetobacter baumannii introduced to an oncological hospital by a patient transferred from a general hospital.

PLOS ONE

Dear Dra. Volkow-Fernández,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your revisions have significantly improved this manuscript, however, they are asking for more. We would appreciate receiving your revised manuscript by May 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In my opinion, the authors solved many of the questions and the manuscript is of interest from a clinical and epidemiological point of view. However, it is important to improve the manuscript in scientific content and the presentation to cover the standards required for publication.

Please, I recommend to include line numbers

\[5\]. "This pathogen is able to grow at various temperatures and pH conditions, so it has the ability to persist in either moist or dry conditions in the hospital environment, thereby contributing to transmission" \[5\] Please include more references in the study and avoid same citation in a paragraph

"identification and antimicrobial susceptibility were determined using the Gram-Negative Identification Panel (BDPhoenixTM automated system, New Jersey, USA)." Please include the MIC values.

"DNA was extracted from a representative strain of each patter" How many AMR patterns did you find?

"A typical pulsed-field gel electrophoresis analysis of selected isolates of A. baumannii and representative plasmid profiles is shown in figure 2." Please include PFGE in methods section.

"First, rpoB's Zone-1\[9\] was amplified to confirm taxonomic status" Amplified and sequenced?

This MLST has been identified previously in Mexican hospitals and in other countries of Latin America. Please include more references to improve the discussion.

It would be important to characterize the resistance mechanisms found in ST758, and if possible, to sequence the strain and the plasmids that will show relevant information to complement the clinical part of the study.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In my opinion, the authors solved many of the questions and the manuscript is of interest from a clinical and epidemiological point of view. However, it is important to improve the manuscript in scientific content and the presentation to cover the standards required for publication.

1\. Please, I recommend to include line numbers

We included line numbers.

2\. \[5\]. "This pathogen is able to grow at various temperatures and pH conditions, so it has the ability to persist in either moist or dry conditions in the hospital environment, thereby contributing to transmission" \[5\] Please include more references in the study and avoid same citation in a paragraph.

Answer: We have included 3 references related to the capacity of the pathogen to survive and multiple in diverse conditions. Page 3. Line 67.

\- Baumann P. Isolation of Acinetobacter from soil and water. J Bacteriol. 1968;96(1):39--42

\- Warskow AL, Juni E. Nutritional requirements of Acinetobacter strains isolated from soil, water, and sewage. J Bacteriol. 1972;112(2):1014--1016.

\- Jawad A, Heritage J, Snelling AM, Gascoyne-Binzi DM, Hawkey PM. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol. 1996;34(12):2881--2887.

3\. "identification and antimicrobial susceptibility were determined using the Gram-Negative Identification Panel (BDPhoenixTM automated system, New Jersey, USA)." Please include the MIC values

MICs values were included. Page 6, lines 126-128.

4\. "DNA was extracted from a representative strain of each patter" How many AMR patterns did you find?

There was the same antimicrobial resistance pattern in all MLST758 samples (n=99, 93.4%). In the remaining 7 strains, there was a minimal difference in the MICs of different antibiotics, including quinolones, beta-lactams, and carbapenems, however they were considered resistant according to CLSI.

5\. "A typical pulsed-field gel electrophoresis analysis of selected isolates of A. baumannii and representative plasmid profiles is shown in figure 2." Please include PFGE in methods section.

There was a mistake in this statement, because we did not perform PFGE. The sentence was changed by: "Representative plasma profiles of selected Acinetobacter strains are shown in figure 2." Page 8, line 179.

6\. "First, rpoB's Zone-1\[9\] was amplified to confirm taxonomic status" Amplified and sequenced?

Yes, amplified and sequenced. Sequenced was added in the sentence. Page 6, line 132. A method to obtain plasmid profiles from Acinetobacter was included as Supplement.

7\. This MLST has been identified previously in Mexican hospitals and in other countries of Latin America. Please include more references to improve the discussion.

We included three references in this part. Page 16, line 270.

\- Alcántar-Curiel MD, Rosales-Reyes R, Jarillo-Quijada MD, et al. Carbapenem-Resistant Acinetobacter baumannii in Three Tertiary Care Hospitals in Mexico: Virulence Profiles, Innate Immune Response and Clonal Dissemination. Front Microbiol 2019; 10: 2116. Published 2019 Sep 20. doi:10.3389/fmicb.2019.02116

\- Tamayo-Legorreta EM, Garza-Ramos U, Barrios-Camacho H, et al. Identification of OXA-23 carbapenemases: novel variant OXA-239 in Acinetobacter baumannii ST758 clinical isolates in Mexico. New Microbes New Infect 2014; 2: 173--4. doi:10.1002/nmi2.60

\- Vanegas JM, Higuita LF, Vargas CA, Cienfuegos AV, Rodríguez EA, Roncancio GE, Jiménez JN. \[Carbapenem-resistant Acinetobacter baumannii causing osteomyelitis and infections of skin and soft tissues in hospitals of Medellín, Colombia\]. Biomedica 2015; 35:522--30.

8\. It would be important to characterize the resistance mechanisms found in ST758, and if possible, to sequence the strain and the plasmids that will show relevant information to complement the clinical part of the study.

Thanks for the comment. We have very recently published a manuscript (see reference below) where we not only characterised the resistance mechanisms in ST758 but also studied the phylogeography of this lineage. Of note, in this study more than 20 ST758 genomes were considered. To enrich our manuscript, we have included a couple of sentences in the discussion (page 18, first paragraph) talking about the resistance mechanisms found in ST758.

Recently, employing a population genomics approach, we described the emergence and dispersion of the lineage ST758, and also studied the antibiotic resistance mechanisms present in strains from this ST (REF mSphere article). This lineage emerged rather recently (about 22 years ago) and since then it has spread in many countries in Latin and North America; notably, strains from this lineage are not only carbapenem resistant but also multidrug resistant. In terms of acquired oxacillinases (OXAs), this lineage presents the worldwide-distributed OXA-23-like family but also the less disseminated OXA-40-like family. Page 18, lines 298-304.

The reference was included: Graña-Miraglia L, Evans BA, López-Jácome LE, et al. Origin of OXA-23 Variant OXA-239 from a Recently Emerged Lineage of Acinetobacter baumannii International Clone V. mSphere. 2020;5(1):e00801-19. Published 2020 Jan 8. doi:10.1128/mSphere.00801-19
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